Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562670 | 0.81 | ERN1 (0.65) | ERN1KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL3156151 | 0.81 | KMT2A (0.59) | ERN1KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL3156135 | 0.79 | ERN1 (0.58) | ERN1KDM4EMAPTALDH1A1L3MBTL1 | |
| SCHEMBL28453350 | 0.78 | ERN1 (0.55) | ERN1KDM4EMAPTSYKALDH1A1 | |
| SCHEMBL30203664 | 0.78 | ERN1 (0.55) | ERN1KDM4EMAPTSYKALDH1A1 | |
| SCHEMBL747786 | 0.77 | ERN1 (0.59) | ERN1KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL3959717 | 0.77 | ERN1 (0.45) | ERN1KDM4EMAPTSYKHPGD | |
| SCHEMBL3148928 | 0.76 | ERN1 (0.41) | ERN1KDM4ESYKHPGDALDH1A1 | |
| SCHEMBL20562170 | 0.76 | ALDH1A1 (0.49) | ERN1MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL3147218 | 0.76 | MAPT (0.54) | ERN1KDM4EMAPTSYKHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1987040-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093963-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-4812471-A | Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones | PFIZER INC. (US) | 1989-03-14 | — | — | US | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | ERN1 757/4885KDM4E 2703/4885MAPT 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.